Metastatic same-site squamous cell carcinoma arising during vismodegib therapy for basal cell carcinoma

[1]  K. Rieger,et al.  Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma. , 2019, The Journal of investigative dermatology.

[2]  M. Chren,et al.  Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib , 2017, Journal of the American Academy of Dermatology.

[3]  A. Henry,et al.  Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma. , 2016, JAMA dermatology.

[4]  Jean Y. Tang,et al.  Squamous Change in Basal-Cell Carcinoma with Drug Resistance. , 2015, The New England journal of medicine.

[5]  B. Dréno,et al.  Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  L. Thomas,et al.  Fast-Growing Cutaneous Squamous Cell Carcinoma in a Patient Treated with Vismodegib , 2015, Dermatology.

[7]  A. Chang,et al.  Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. , 2014, JAMA dermatology.

[8]  J. Utikal,et al.  Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma , 2014, The British journal of dermatology.

[9]  V. Sondak,et al.  Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. , 2013, Journal of the American Academy of Dermatology.

[10]  J. Kolesar,et al.  Vismodegib for the treatment of basal cell skin cancer. , 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.